Lubris

Novartis in-licensing ECF843 for ophthalmic indications

Tuesday, April 11, 2017

Novartis announced that it has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe). The closing of the deal is subject to customary closing conditions including regulatory approvals. The financial and other terms of this transaction are not disclosed.

[Read More]